Fig. 6: Serum Neuregulin1α levels increase in MASLD human subjects with obesity.
a Immunoblotting of Neuregulin1α in culture medium from isolated hepatocytes. Lanes 1&2, 16, and 8 μl of 100 x concentrated culture medium from mouse hepatocytes (3.5 × 105 cells/mL); Lanes 3&4, 16, and 8 μl of 100 x concentrated culture medium from human hepatocytes (7.6 × 105 cells/mL) isolated from PXB mice. This experiment was repeated twice independently. b, c Correlation of levels of hepatic type I Neuregulin1 (Nrg1) mRNA with serum Neuregulin1α protein (NRG1α) (b), and hepatic Neuregulin1α mRNA with serum NRG1α (c) from metabolic dysfunction associated steatotic liver disease (MASLD) patients. χ2 tests were used for statistical analysis. n = 25. d, e Levels of serum Neuregulin1α from MASLD patients. d: comparison of serum NRG1α levels among MASLD patients. The MASLD group was divided into three groups depending on obesity. e: comparison of serum Neuregulin1α levels in MASLD patients with obesity and diabetes. n = 36 (BMI < 25), 36 (25 ≤ BMI < 30), 42 (30 ≤ BMI), and 38 (diabetes) individuals with MASLD per group. Single regression analysis (two-tailed Spearman’s correlation coefficient) (b, c), a Kruskal-Wallis test (d), and a two-tailed Mann-Whitney U test (e) were performed.
